Compare · AVTR vs QTRX
AVTR vs QTRX
Side-by-side comparison of Avantor Inc. (AVTR) and Quanterix Corporation (QTRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AVTR and QTRX operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- AVTR is the larger of the two at $6.62B, about 44.9x QTRX ($147.4M).
- Over the past year, AVTR is down 25.9% and QTRX is down 40.0% - AVTR leads by 14.2 points.
- QTRX has been more active in the news (9 items in the past 4 weeks vs 3 for AVTR).
- AVTR has more recent analyst coverage (25 ratings vs 13 for QTRX).
- Company
- Avantor Inc.
- Quanterix Corporation
- Price
- $9.97+2.99%
- $3.04-2.88%
- Market cap
- $6.62B
- $147.4M
- 1M return
- +20.18%
- +7.24%
- 1Y return
- -25.86%
- -40.02%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- 2017
- News (4w)
- 3
- 9
- Recent ratings
- 25
- 13
Avantor Inc.
Avantor, Inc. provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, and clinical trial kits. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Avantor, Inc. was founded in 1904 and is headquartered in Radnor, Pennsylvania.
Quanterix Corporation
Quanterix Corporation, a life sciences company, develops and markets digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assay kits and other consumables such as reagents. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
Latest AVTR
- Wolfe Research resumed coverage on Avantor with a new price target
- SEC Form SD filed by Avantor Inc.
- Avantor® Announces Gerard (Jerry) Porreca as Executive Vice President, Quality and Regulatory
- RBC Capital Mkts resumed coverage on Avantor with a new price target
- Avantor Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Director Murthy Mala was granted 25,270 shares, increasing direct ownership by 57% to 69,479 units (SEC Form 4)
- Director Lucier Gregory T was granted 25,270 shares and bought $83,200 worth of shares (10,000 units at $8.32), increasing direct ownership by 289% to 34,006 units (SEC Form 4)
- Director Dingemans Simon was granted 25,270 shares, increasing direct ownership by 406% to 31,495 units (SEC Form 4)
- Director Massaro Joseph R was granted 25,270 shares, increasing direct ownership by 48% to 77,408 units (SEC Form 4)
- Director Makin Louise was granted 25,270 shares, increasing direct ownership by 116% to 47,140 units (SEC Form 4)
Latest QTRX
- Quanterix Corporation filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Quanterix Announces Appointment of Jason Faessler as Chief Financial Officer
- Quanterix Appoints Industry Veteran Geoff Albrecht as Senior Vice President and General Manager of Diagnostics
- Quanterix To Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
- Chief Technology Officer Miller Michael Francis converted options into 130 shares and covered exercise/tax liability with 39 shares, increasing direct ownership by 0.27% to 33,795 units (SEC Form 4)
- Quanterix Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Chief Financial Officer Sriram Vandana converted options into 1,833 shares and covered exercise/tax liability with 548 shares, increasing direct ownership by 4% to 29,998 units (SEC Form 4)
- Chief Technology Officer Miller Michael Francis converted options into 1,558 shares and covered exercise/tax liability with 467 shares, increasing direct ownership by 3% to 33,704 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Quanterix Corporation